Bristol Myers Squibb Co. (BMY)

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

They buy and buy and buy. The same stocks. Over and over. No end to it.

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

At the end of the day, investors really have only three choices to make when managing an investment portfolio -- buy, hold, or sell.

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Merger activity is the number 1 driver I am watching for biotech growth.

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

These companies all could be strong -- even if the 2019 nCoV fear spreads.

BlackRock's CEO will now make investment decisions based on a company's commitment to environmental sustainability. You can bet the financial world will never be the same again.

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

Let's review the charts.

The Medical Technology Stock Letter's top pick rose 357% in 2019.

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.

We are playing defense as we see some downward pressure on oil and healthcare weakness.

There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.

We're seeing lots of companies snapping up their peers, and the market is applauding.

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

BMY can soar still higher in the months ahead.